This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Argenx Bvba, Universitè Catholique De Louvain, Université Catholique De Louvian. Active years: 2019-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Wezembeek-Oppem, BE (2019)
- Sawston, GB (2020)
Company Filing History:
2 out of 13 
1 out of 100 
1 out of 1 Years Active: 2019-2020
Title: Stéphanie Liénart: Innovator in Antibody Development
Introduction
Stéphanie Liénart is a notable inventor based in Sawston, GB. He has made significant contributions to the field of antibody development, holding two patents that showcase his innovative work. His research focuses on antibodies that interact with the GARP-TGF-β1 complex, which has important implications for therapeutic applications.
Latest Patents
Liénart's latest patents include the development of GARP-TGF-β1 IGG antibodies. These inventions relate to antibodies and antigen binding fragments that bind to a complex of GARP and TGF-β1, particularly the human variants. The antibodies exhibit high affinity for antigen binding and can inhibit the release of active TGF-β from regulatory T cells. Additionally, these antibodies are designed to be resistant to deamidation, isomerization, and oxidation, which enhances their stability.
Career Highlights
Throughout his career, Stéphanie Liénart has worked with prominent organizations such as Argenx Bvba and Université Catholique De Louvain. His experience in these institutions has allowed him to refine his expertise in antibody research and development.
Collaborations
Some of his notable coworkers include Sebastian Paul Van Der Woning and Filip Borgions. Their collaborative efforts have contributed to advancements in the field of immunology.
Conclusion
Stéphanie Liénart's work in antibody development represents a significant advancement in therapeutic research. His innovative patents and collaborations highlight his commitment to improving medical treatments through scientific discovery.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile